GlobalRPh Renal Dosing Masterv7.4
Renal Dosing Master: fast drug lookup
Source review / handoff

Tolcapone (Tasmar), oral tablet

One or two intact local summaries. No averaged regimen, patient-specific dose or automatic source preference.

Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.

Share or print this source review

1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.

Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.

Clinical context remains essential

Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.

Check source scope before reading a dose

Tasmar - labeled renal guidance

Product / population
Tolcapone (Tasmar), oral tablet
Renal method
Renal impairment categories as defined by the cited product label
Source revision
DailyMed SPL version 13, posted Jan 05, 2021
Retrieved
2026-11-07
Local review status
Selected renal passages reviewed; independent clinician adjudication pending.

Documented differences and cautions on this drug

All record notes are retained here, including notes about sources not selected in this review.

Tasmar - product and source limitations

Follow the separate liver safety and monitoring requirements for tolcapone.

What to reconcile: Verify the current prescribing information for this presentation.

Selected renal passages reviewed; independent clinician adjudication pending.

Open this note and its source references
Official

Tasmar - labeled renal guidance

Open original reference

DailyMed / product prescribing information · Tolcapone (Tasmar), oral tablet

Renal method: Renal impairment categories as defined by the cited product label
Source date: DailyMed SPL version 13, posted Jan 05, 2021
Retrieved: 2026-11-07

Qualified no-adjustment statement. Apply only to the population, product and renal range described in this source.

Selected renal passages reviewed; independent clinician adjudication pending.

Renal guidance: Renal Impairment: / Patients With Impaired Renal Function:

The label permits usual dosing in mild or moderate renal impairment and advises caution in severe impairment. Follow the separate liver safety and monitoring requirements for tolcapone.

RDM74-tasmar-official-1 · Source locator: Renal guidance: Renal Impairment: / Patients With Impaired Renal Function:

Source identity and provenance
Source family
product_label
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a0e47a9d-78e7-4523-983a-aa259f221736
Retrieved
2026-11-07
Renal-function method
Renal impairment categories as defined by the cited product label
Source date/version
DailyMed SPL version 13, posted Jan 05, 2021
Hash meaning
SHA-256 of the local selected-source summary
Local summary SHA-256
6b5bd48010d6b2c0584844237b10fc39145a4a91d20353cb6e197b86de700ccc

Document the clinical decision separately

This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.

GlobalRPh Renal Dosing Master v7.4. Review the retrieval and revision dates attached to each source. Selecting a reference does not imply clinical verification.

Pinned reference: https://globalrph.com/blogCalcs/renal-dosing-master/compare.php?id=rx-tasmar&s1=RDM74-tasmar-official&h1=71f22036853b6f64570699e6816352e614bbbaeb707152fe8aa98db8af021363

Top